scholarly journals Antinociceptive effects of magnetic stimulation in the rat neuropathic pain model

PAIN RESEARCH ◽  
2011 ◽  
Vol 26 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Kazuo Okamoto ◽  
Nozomi Ami ◽  
Yukinori Kubotera ◽  
Hidehiko Ooshima ◽  
Hozumi Tatsuoka
Keyword(s):  
Neuropathic Pain ◽  
Magnetic Stimulation ◽  
Pain Model ◽  
Antinociceptive Effects ◽  
Neuropathic Pain Model

scholarly journals 159 THE ANTINOCICEPTIVE EFFECTS OF GABAPENTIN AND NITRIC OXIDE ON NEUROPATHIC PAIN MODEL FORMED IN RATS

2010 ◽  
Vol 4 (S1) ◽  
pp. 48-48
Author(s):  
F. Sekdur ◽  
O.N. Aydin ◽  
B. Alacam ◽  
M. Ogurlu ◽  
S. Temocin ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Neuropathic Pain ◽  
Pain Model ◽  
Antinociceptive Effects ◽  
Neuropathic Pain Model

scholarly journals Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain

2022 ◽  
Vol 15 (1) ◽  
pp. 88
Author(s):  
Renata Zajączkowska ◽  
Ewelina Rojewska ◽  
Agata Ciechanowska ◽  
Katarzyna Pawlik ◽  
Katarzyna Ciapała ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Clinical Use ◽  
Clinical Perspective ◽  
Pain Model ◽  
Clinical Challenge ◽  
Antinociceptive Effects ◽  
New Strategy ◽  
Neuropathic Pain Model ◽  
Crucial Information ◽  
Spinal Cord Level

Neuropathic pain remains a difficult clinical challenge due to its diverse aetiology and complex pathomechanisms, which are yet to be fully understood. Despite the variety of available therapies, many patients suffer from ineffective pain relief; hence, the search for more efficacious treatments continues. The new gabapentinoid, mirogabalin has recently been approved for clinical use. Although its main mechanism of action occurs at the α2σ-1 and α2σ-2 subunits of calcium channels and is well documented, how the drug affects the disturbed neuropathic interactions at the spinal cord level has not been clarified, which is crucial information from a clinical perspective. The findings of our study suggest that several indirect mechanisms may be responsible for the beneficial analgesic effect of mirogabalin. This is the first study to report that mirogabalin enhances the mRNA expression of spinal antinociceptive factors, such as IL-10 and IL-18BP, and reduces the concentration of the pronociceptive substance P. Importantly, mirogabalin improves the morphine-, buprenorphine-, oxycodone-, and ketamine-induced antinociceptive effects in a neuropathic pain model. Our findings support the hypothesis that enhancing opioid and ketamine analgesia by combining these drugs with mirogabalin may represent a new strategy for the effective pharmacotherapy of neuropathic pain.

Phα1β, a Peptide from the Venom of the Spider Phoneutria Nigriventer Shows Antinociceptive Effects after Continuous Infusion in a Neuropathic Pain Model in Rats

2014 ◽  
Vol 119 (1) ◽  
pp. 196-202 ◽  
Author(s):  
Fernanda Rosa ◽  
Gabriela Trevisan ◽  
Flávia Karine Rigo ◽  
Raquel Tonello ◽  
Edinéia Lemos Andrade ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Continuous Infusion ◽  
Pain Model ◽  
Antinociceptive Effects ◽  
Neuropathic Pain Model ◽  
Phoneutria Nigriventer

scholarly journals Antinociceptive Effects of Amiloride and Benzamil in Neuropathic Pain Model Rats

2013 ◽  
Vol 28 (8) ◽  
pp. 1238 ◽  
Author(s):  
Seongtae Jeong ◽  
Seong Heon Lee ◽  
Yeo Ok Kim ◽  
Myung Ha Yoon
Keyword(s):  
Neuropathic Pain ◽  
Pain Model ◽  
Antinociceptive Effects ◽  
Neuropathic Pain Model

scholarly journals The activation of galanin receptor 2 plays an antinociceptive effect in nucleus accumbens of rats with neuropathic pain

2021 ◽  
Vol 71 (1) ◽  
Author(s):  
Yan Dong ◽  
Chong-Yang Li ◽  
Xiao-Min Zhang ◽  
Ya-Nan Liu ◽  
Shuang Yang ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Nucleus Accumbens ◽  
Pain Threshold ◽  
Antinociceptive Effect ◽  
Galanin Receptor ◽  
Pain Model ◽  
Withdrawal Threshold ◽  
Neuropathic Pain Model ◽  
Galanin Receptors ◽  
Intact Rats

AbstractOur previous research has shown that galanin plays an antinociceptive effect via binding to galanin receptors (GalRs) in nucleus accumbens (NAc). This study focused on the involvement of GalR2 in galanin-induced antinociceptive effect in NAc of neuropathic pain rats. The chronic constriction injury of sciatic nerve (CCI) was used to mimic neuropathic pain model. The hind paw withdrawal latency (HWL) to thermal stimulation and hind paw withdrawal threshold (HWT) to mechanical stimulation were measured as the indicators of pain threshold. The results showed that 14 and 28 days after CCI, the expression of GalR2 was up-regulated in bilateral NAc of rats, and intra-NAc injection of GalR2 antagonist M871 reversed galanin-induced increases in HWL and HWT of CCI rats. Furthermore, intra-NAc injection of GalR2 agonist M1145 induced increases in HWL and HWT at day 14 and day 28 after CCI, which could also be reversed by M871. Finally, we found that M1145-induced antinociceptive effect in NAc of CCI rats was stronger than that in intact rats. These results imply that the GalR2 is activated in the NAc from day 14 to day 28 after CCI and GalR2 is involved in the galanin-induced antinociceptive effect in NAc of CCI rats.

scholarly journals Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model

2021 ◽  
Vol 22 (5) ◽  
pp. 2479
Author(s):  
Amir Mohammadzadeh ◽  
Péter P. Lakatos ◽  
Mihály Balogh ◽  
Ferenc Zádor ◽  
Dávid Árpád Karádi ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Animal Studies ◽  
Acute Administration ◽  
Pain Model ◽  
Therapeutic Value ◽  
Small Doses ◽  
Function Test ◽  
Neuropathic Pain Model ◽  
First Time ◽  
Glycine Content

The limited effect of current medications on neuropathic pain (NP) has initiated large efforts to develop effective treatments. Animal studies showed that glycine transporter (GlyT) inhibitors are promising analgesics in NP, though concerns regarding adverse effects were raised. We aimed to study NFPS and Org-25543, GlyT-1 and GlyT-2 inhibitors, respectively and their combination in rat mononeuropathic pain evoked by partial sciatic nerve ligation. Cerebrospinal fluid (CSF) glycine content was also determined by capillary electrophoresis. Subcutaneous (s.c.) 4 mg/kg NFPS or Org-25543 showed analgesia following acute administration (30–60 min). Small doses of each compound failed to produce antiallodynia up to 180 min after the acute administration. However, NFPS (1 mg/kg) produced antiallodynia after four days of treatment. Co-treatment with subanalgesic doses of NFPS (1 mg/kg) and Org-25543 (2 mg/kg) produced analgesia at 60 min and thereafter meanwhile increased significantly the CSF glycine content. This combination alleviated NP without affecting motor function. Test compounds failed to activate G-proteins in spinal cord. To the best of our knowledge for the first time we demonstrated augmented analgesia by combining GlyT-1 and 2 inhibitors. Increased CSF glycine content supports involvement of glycinergic system. Combining selective GlyT inhibitors or developing non-selective GlyT inhibitors might have therapeutic value in NP.

Sign in / Sign up

Export Citation Format

Share Document